Abbott CEO Miles White said that he is confident that Abbott's acquisition of Alere will close as expected before the end of Q3.
About 63 million votes were in favor of the deal, representing more than 72.5 percent of all outstanding Alere shares as of the May 31 record date.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
Abbott CEO Miles White said that while Alere is a bit of a fixer upper, he is pleased to have a resolution to issues surrounding the proposed acquisition.
The firms also dropped their lawsuits against each other, and said they expect to complete the merger by the end of the third quarter.
The New York Stock Exchange gave Alere an additional six months to file its 2016 annual report, but it also said it could commence delisting proceedings at any time.
Researchers and companies move to develop blood-based tests for concussion, according to Scientific American.
The firm wants to develop a test that can provide objective, reliable, and rapid information so that clinicians can make critical decisions in circumstances of high uncertainty.
The FDA granted Abbott Emergency Use Authorization for the assay in serum, plasma, and urine in November.
Abbott's commitment to closing the deal is still uncertain, but Alere's CEO said the regulatory clearance marks a "significant milestone."
A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.
South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.
In Science this week: the synthetic genetic system hachimoji, and more.
Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.